This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
The Managerial Dilemma of E-Toll Route Implementation in South Africa
Ntoi, Hlompho; Thomas, Lawrence; Vilà, JoaquimCase SM-1643-EDecision Analysis, Innovation and Change, StrategyIn 2007, South African National Roads Agency Ltd (SANRAL) decided to introduce a radical and advanced urban tolling system called the Gauteng Freeway Improvement Project (GFIP). The project entailed the expansion of the province's single-direction three-lane highways to single-direction five-lane routes. Large toll gantries were to be built in order to process usage data as a means of billing users electronically via a strict user pay system. P...Starting at €8.20
-
The Michelin Group India: Handling Accusations of Misconduct - Teaching Note
Alison E. HolmTeaching Note IVEY-W26664-EStrategyTeaching note for product W26663.Starting at €0.00
-
The Vitality Group: Paying for Self-Care
Herzlinger, Regina E.Case HBS-310071-EEntrepreneurshipVitality is part of a $2 billion start-up South African and U.K. health insurance firm. It has achieved excellent results in rewarding people for promoting their health. It is now contemplating how to enter the U.S. market.Starting at €8.20
-
New Earth Mining, Inc., Teaching Note
Fruhan, William E.; Wang, WeiTeaching Note HBS-913549-EFinanceTeaching Note for Product #913548.Starting at €0.00
-
Bonitas
Herzlinger, Regina E.; Kindred, NatalieCase HBS-315020-EBonitas, a South African medical scheme (i.e., health insurer), must navigate highly restrictive regulations that make it difficult for Bonitas to innovate, grow, and compete with market leader Discovery as well as providers of alternative insurance products. Bonitas (HBS No. 315-020) must also plan ahead for the rollout of national health insurance-a deeply politicized issue in a country with great disparities in health care quality and access. ...Starting at €8.20
-
New Earth Mining, Inc.
Fruhan, William E.; Wang, WeiCase HBS-913548-EFinanceNew Earth Mining is one of the largest producers of precious metals in the U.S. While the firm operates mines primarily in the U.S. and Canada, it has also made substantial investments in gold exploration projects in Australia and Chile. New Earth has been very successful and has a large amount of cash on the balance sheet, a simple debt structure, and a reasonable leverage ratio with liquidity risk. With a strong financial position, the firm con...Starting at €8.20
-
New Earth Mining, Inc. (Spanish version)
Fruhan, William E.; Wang, WeiCase HBS-917S19FinanceNew Earth Mining is one of the largest producers of precious metals in the U.S. While the firm operates mines primarily in the U.S. and Canada, it has also made substantial investments in gold exploration projects in Australia and Chile. New Earth has been very successful and has a large amount of cash on the balance sheet, a simple debt structure, and a reasonable leverage ratio with liquidity risk. With a strong financial position, the firm con...Starting at €8.20
-
Discovery Limited
Porter, Michael E.; Kramer, Mark R.; Sesia, AldoCase HBS-715423-EStrategyDiscovery Ltd. is a South-African based insurance company. Started in the early 1990s, Discovery used behavioral economics and data collection to innovate in the health care insurance industry. Its founder Adrian Gore believed that the company's products needed to not only make money but have a positive impact on society. Using its Vitality Wellness program as its strategic lynchpin, Discovery expanded into other insurance areas and financial ser...Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
John Roux at Con Roux Construction - Teaching Note
Miller, PaddyTeaching Note FHT-40-ELeadership and People Management(see case FH-697-E)Starting at €0.00